Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.